It should be noted that ...

It should be noted that during the reception Eneriona there were no signs of deterioration in patients with atrial fibrillation. In general, the use of Eneriona found safe in various forms of somatic pathology in geriatric patients. None of the observations was not required to make changes in the basic treatment of concomitant diseases, which also indicated the stability somatonevrologicheskogo of patients during treatment Enerionom. The drug is generally well tolerated by elderly patients. However, the possibility of cutaneous allergic reactions necessitates careful preliminary study of allergic history in general and particularly in relation tiaminovyh derivatives, informing patients about the risk of such side effects, careful monitoring of patients in the first week of taking the medication and taking the necessary steps in identifying intolerances. The drug Enerion (salbutiamin) certainly has a pronounced antiastenicheskimi properties, eliminating the first signs of general physical fatigue, later weakening manifestations of mental fatigue and greatly reducing the severity of symptoms somatovegetative asthenia patients elderly. Treatment Enerionom provides recovery of activity and performance, increase endurance to physical exercise and tolerance psychotraumatic effects, improved sleep, reduced anxiety in actual and personal manifestations. At the same time during the treatment Enerionom marked improvement in cognitive function, primarily by improving concentration, self-discipline of thinking, to increase the activity, some acceleration of the rate of mental processes. Therapeutic effect is detected quickly enough, since clearly manifested after the first week of dosing and growing by the end of month course of therapy. The study showed the efficacy and tolerability Eneriona in geriatric patient population, use of the drug is effective not only in patients with functional mental disorders, but certainly effectively with psevdonevrastenicheskih violations within psychoorganic syndrome of vascular origin. Enerion was effective during prolonged asthenic disorders are often poorly respondents to the previously ongoing therapy nootropics and tranquilizers. According to the subjective assessment of patients antiastenichesky therapeutic effect Eneriona surpassed the results of treatment with other medicines, shall be appointed for the same purpose. In general, marked by relatively high satisfaction of patients with treatment outcomes Enerionom, as evidenced by the fact that upon completion of clinical studies, some patients subsequently tried to repeat the treatment course, buying the drug on their own. Enerion well tolerated in elderly patients with multiple somatic pathology, easy to use in connection with a single dose during the day.